Reports
Sale
Primary Myelofibrosis Market Size, Share, Trends, Report: By Type: Spinocerebellar Primary Myelofibrosis, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Others; By Services: Treatment, Diagnosis; By Dosage Forms: Solid, Liquid, Others; By Age: Children, Others; By End User: Regional Analysis; Supplier Landscape; 2024-2032
Primary Myelofibrosis Market Outlook
The primary myelofibrosis market size was valued at USD 877.43 million in 2023, driven by the increasing prevalence of myelofibrosis across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 to achieve a value of USD 1438.9 million by 2032.
Primary Myelofibrosis: Introduction
Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It is a type of chronic leukemia that involves too many abnormal blood cells being made. Eventually, these cells can replace normal cells. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
Primary Myelofibrosis Market Analysis
The market growth is driven by the increased prevalence of primary myelofibrosis. The key market players are increasing their efforts toward discovering and producing the best and most effective treatment options to increase life expectancy worldwide. The recent developments in the field of myelofibrosis have been exhibited by the FDA approval of Ojjaara (momelotinib) by GSK plc and the Fast Track Designation granted to selinexor by Karyopharm Therapeutics Inc., are anticipated to have a significant positive impact on the growth of the primary myelofibrosis market.
People with myelofibrosis often develop anemia, which is a problem resulting in more than 30% of patients discontinuing the treatment. Recently, the FDA has approved a new medicine called Ojjaara. This once-a-day pill targets JAK1, JAK2, and ACVR1. This medicine has exclusively been made for those with intermediate or high-risk myelofibrosis, including both primary and secondary types. By effectively targeting key disease manifestations such as anemia, constitutional symptoms, and splenomegaly, Ojjaara is poised to offer a comprehensive therapeutic solution and boost the primary myelofibrosis market growth.
Furthermore, the Fast Track Designation granted to selinexor exemplifies the industry's commitment to advancing innovative therapies for myelofibrosis patients, reflecting a proactive approach to expedite the development of potential treatments. As ongoing clinical trials explore various therapeutic options, the forecast period is expected to witness a surge in FDA-approved treatments for myelofibrosis, thereby propelling the growth of the primary myelofibrosis market. This increase in approved treatments not only expands the spectrum of available therapeutic interventions but also addresses the unmet needs of patients, contributing to the overall advancement of myelofibrosis care.
Primary Myelofibrosis Market Segmentations
Market Breakup by Type
- Spinocerebellar Primary Myelofibrosiss
- Primary Myelofibrosis-Telangiectasia
- Episodic Primary Myelofibrosis
- Others
Market Breakup by Services
- Treatment
- Diagnosis
Market Breakup by Dosage Forms
- Solid
- Liquids
- Others
Market Breakup by Age
- Adult
- Child
- Geriatric
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Primary Myelofibrosis Market Overview
The increasing emphasis on research and development activities by key players is expected to potentially create lucrative opportunities for primary myelofibrosis treatment market growth. Primary myelofibrosis is a rare disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The incidence rate of myelofibrosis ranged from 0.1 to 1 case per 100,000 per year. The additional market growth can be attributed to the increasing awareness regarding Primary Myelofibrosis (PMF) treatment and the rise in the number of patients is also poised to result in increased production of more effective and targeted treatment drugs and JAK inhibitors.
The healthcare sector has been improving, and favorable government initiatives, reimbursement policies, and changing dietary patterns are collectively contributing to the primary myelofibrosis market growth. These factors, along with the busy lifestyle, are contributing to the growth of the market. Additionally, the market is expected to grow further due to increased investments in research and development activities aimed at developing precise treatments for myelofibrosis in the forecast period.
Geographically, North America is currently dominating the regional market and is expected to drive market growth in the forecast period as well. The market growth is expected to be driven by the increased research and development activities by key players in order to develop more effective and targeted treatment options for the patients, resulting in better patient outcomes. Also, the presence of some of the key players in the region is also propelling the market growth.
Primary Myelofibrosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bristol-Myers Squibb Company
- Amneal Pharmaceuticals, Inc.
- CTI BioPharma Corp
- Actuate Therapeutics Inc.
- Pfizer Inc.
- Galecto
- Incyte Corporation
- AbbVie Inc.
- GlaxoSmithKline plc
- Imago BioSciences
- Sanofi
- F. Hoffmann-La Roche Ltd
- Mylan NV
- Hikma Pharmaceuticals PLC
- Bayer AG
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Services |
|
| Breakup by Dosage Forms |
|
| Breakup by Age |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Primary Myelofibrosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Primary Myelofibrosis Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3.1 Germany Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3.2 France Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3.3 Italy Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3.4 Spain Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Primary Myelofibrosis Epidemiology Forecast (2017-2032)
5.4 Japan Primary Myelofibrosis Epidemiology Forecast (2017-2032)
6 Primary Myelofibrosis Market Overview – 7MM
6.1 Primary Myelofibrosis Market Historical Value (2017-2023)
6.2 Primary Myelofibrosis Market Forecast Value (2024-2032)
7 Primary Myelofibrosis Market Landscape – 7MM
7.1 Primary Myelofibrosis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Primary Myelofibrosis Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Primary Myelofibrosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Primary Myelofibrosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Primary Myelofibrosis Market Segmentation – 7MM
11.1 Primary Myelofibrosis Market by Type
11.1.1 Market Overview
11.1.2 Spinocerebellar Primary Myelofibrosis
11.1.3 Primary Myelofibrosis-Telangiectasia
11.1.4 Episodic Primary Myelofibrosis
11.1.5 Others
11.2 Primary Myelofibrosis Market by Services
11.2.1 Market Overview
11.2.2 Treatment
11.2.3 Diagnosis
11.3 Primary Myelofibrosis Market by Dosage Forms
11.3.1 Market Overview
11.3.2 Solid
11.3.3 Liquid
11.3.4 Others
11.4 Primary Myelofibrosis Market by Age
11.4.1 Market Overview
11.4.2 Children
11.4.3 Adult
11.4.4 Geriatric
11.5 Primary Myelofibrosis Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Others
11.6 Primary Myelofibrosis Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Primary Myelofibrosis Market
12.1 Primary Myelofibrosis Market Historical Value (2017-2023)
12.2 Primary Myelofibrosis Market Forecast Value (2024-2032)
12.3 Primary Myelofibrosis Market by Disease Type
12.4 Primary Myelofibrosis Market by Treatment Type
13 EU-4 and United Kingdom Primary Myelofibrosis Market
13.1 Primary Myelofibrosis Market Historical Value (2017-2023)
13.2 Primary Myelofibrosis Market Forecast Value (2024-2032)
13.3 Germany Primary Myelofibrosis Market Overview
13.3.1 Primary Myelofibrosis Market by Disease Type
13.3.2 Primary Myelofibrosis Market by Treatment Type
13.4 France Primary Myelofibrosis Market Overview
13.4.1 Primary Myelofibrosis Market by Disease Type
13.4.2 Primary Myelofibrosis Market by Treatment Type
13.5 Italy Primary Myelofibrosis Market Overview
13.5.1 Primary Myelofibrosis Market by Disease Type
13.5.2 Primary Myelofibrosis Market by Treatment Type
13.6 Spain Primary Myelofibrosis Market Overview
13.6.1 Primary Myelofibrosis Market by Disease Type
13.6.2 Primary Myelofibrosis Market by Treatment Type
13.7 United Kingdom Primary Myelofibrosis Market Overview
13.7.1 Primary Myelofibrosis Market by Disease Type
13.7.2 Primary Myelofibrosis Market by Treatment Type
14 Japan Primary Myelofibrosis Market
14.1 Primary Myelofibrosis Market Historical Value (2017-2023)
14.2 Primary Myelofibrosis Market Forecast Value (2024-2032)
14.2.1 Primary Myelofibrosis Market by Disease Type
14.2.2 Primary Myelofibrosis Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Bristol-Myers Squibb Company
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Amneal Pharmaceuticals, Inc.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 CTI BioPharma Corp
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Actuate Inc.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Pfizer Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Galecto
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Incyte Corporation
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 AbbVie Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 GlaxoSmithKline plc
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Imago BioSciences
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Sanofi
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 F. Hoffmann-La Roche Ltd
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Mylan NV
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Hikma Pharmaceuticals PLC
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Bayer AG
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Primary Myelofibrosis Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 877.43 million in 2023, driven by the increased prevalence of the condition.
The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 1438.9 million by 2032.
The approval of newly developed targeted drugs to treat primary myelofibrosis is driving the market growth.
The clinical development and continuous efforts of scientists to discover new JAK inhibitors to find better treatments for primary myelofibrosis are major trends influencing the market growth.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain) and United Kingdom.
Different types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, and episodic primary myelofibrosis, among others.
The services can be categorised into treatment and diagnosis.
The dosage forms include solid and liquid, among others.
The condition can affect condition can affect people from children to adults to geriatric.
The end-users can be divided into hospitals and clinics, among others.
Key players involved in the market are Bristol-Myers Squibb Company, Amneal Pharmaceuticals, Inc., CTI BioPharma Corp, Actuate Therapeutics Inc., Pfizer Inc., Galecto, Incyte Corporation, AbbVie Inc., GlaxoSmithKline plc, Imago BioSciences, Sanofi, F. Hoffmann-La Roche Ltd, Mylan NV, Hikma Pharmaceuticals PLC, and Bayer AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER